Sagimet Biosciences Inc.
NASDAQ:SGMTBiotechnology
+$0.09 today
- Market cap
- $711.15M
- Beta
- 3.44
- P/E (TTM)
- -5.0
- EPS (TTM)
- -$1.34
Volume 0.93M
Average 1.49M
SGMT Total Assets
Everything the company owns or controls; equal to total liabilities plus equity.
Sagimet Biosciences Inc.NASDAQ: SGMT
Total Assets · Q1 FY2026 · quarter ended Mar 2026
Total assets falls 26.3% from a year ago
Total assets stood at $107.76M at the end of Q1 FY2026, down 26.3% from a year earlier and down 7.5% from the prior quarter. Over 3 fiscal years it compounded at +52.2% a year.
Context
- Total assets increased in 2 of the last 3 fiscal years.
What to watch
Whether total assets keeps falling in the next quarterly balance sheet after a -26.3% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Total Assets history
USD · from the balance sheet
- Latest · FY2025
- 116.48M USD
- Year-over-year change
- -27.3%
- 4-year CAGR
- +18.5%
| Period | Period end | Total Assets | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 116.48M | -27.3% |
| FY2024 | 2024-12-31 | 160.26M | +65.7% |
| FY2023 | 2023-12-31 | 96.72M | +192.8% |
| FY2022 | 2022-12-31 | 33.03M | -44.0% |
| FY2021 | 2021-12-31 | 59.03M | — |
Total Assets vs competitors
How SGMT compares with its peers on the latest reported figures
- SGMT's Mar 2026 total assets of $107.76M is the 10th highest of the 11 companies compared; the peer median is $232.07M.
- Its year-over-year change of -26.3% is the 7th highest of 11, against a peer median of -20.1%.
- Over three fiscal years its annual growth of +52.2% compares with a peer median of +13.1%.
| Company | Period | Latest balance | YoY | 3-year CAGR |
|---|---|---|---|---|
| Mar 2026 | $214.81B | +423744.3% | +23.8% | |
| Mar 2026 | $335.52M | -31.0% | +14.4% | |
| Mar 2026 | $267.08M | -39.3% | -22.1% | |
| Mar 2026 | $245.41M | -26.0% | -15.6% | |
| Mar 2026 | $235.51M | +137.8% | +36.3% | |
ZURAZura Bio Limited | Mar 2026 | $228.64M | +32.5% | +178.7% |
| Mar 2026 | $222.17M | -14.1% | -21.2% | |
| Mar 2026 | $219.33M | -37.9% | +16.5% | |
| Mar 2026 | $110.56M | -32.0% | -17.1% | |
SGMTSagimet Biosciences Inc. | Mar 2026 | $107.76M | -26.3% | +52.2% |
| Mar 2026 | $33.1M | +21.0% | +11.7% | |
| Peer median (excluding SGMT) | $232.07M | -20.1% | +13.1% | |
Competitors are the stored peer set for SGMT. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Sagimet Biosciences Inc.
NASDAQ:SGMT
Intrinsic Alpha fair value
Locked
Current Price
$10.11
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.